We have studied the ventilatory responses to transient hyperoxia in two groups of patients (n:10) anaesthetized with isoflurane (0.3 MAC); patients were allocated randomly to receive either domperidone or placebo orally before anaesthesia. In each patient, five two-breath oxygen tests were averaged and minute ventilation (VE inst ) or mean inspiratory flow rate (VT/TI) for each post-test breath was compared with the mean values for these variables during baseline ventilation. A decrease to less than the 95% confidence limits of mean baseline values was considered a definite response. According to this definition, transient hyperoxia decreased VE inst in nine of 10 patients in the placebo group and in all patients in the domperidone group. Similar changes occurred in VT/TI, with eight of 10 definite responses in the placebo group and 10 of 10 in the domperidone group. Compared with placebo, in the domperidone group there were larger changes in VE inst (0.30 vs 0.55 litre min
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Summary
We have studied the ventilatory responses to transient hyperoxia in two groups of patients (n:10) anaesthetized with isoflurane (0.3 MAC); patients were allocated randomly to receive either domperidone or placebo orally before anaesthesia. In each patient, five two-breath oxygen tests were averaged and minute ventilation (VE inst ) or mean inspiratory flow rate (VT/TI) for each post-test breath was compared with the mean values for these variables during baseline ventilation. A decrease to less than the 95% confidence limits of mean baseline values was considered a definite response. According to this definition, transient hyperoxia decreased VE inst in nine of 10 patients in the placebo group and in all patients in the domperidone group. Similar changes occurred in VT/TI, with eight of 10 definite responses in the placebo group and 10 of 10 in the domperidone group. Compared with placebo, in the domperidone group there were larger changes in VE inst (0.30 vs 0.55 litre min
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(P:0.05)) and VT/TI (8.5 vs 26. 6 Knill and co-workers have shown that the ventilatory response to hypoxia (HVR) in humans is easily depressed by volatile anaesthetics. [1] [2] [3] Anaesthetic concentrations of halothane, enflurane and isoflurane virtually abolished HVR and even subanaesthetic concentrations of these agents reduced the response considerably. However, recent studies have shown that HVR is not as sensitive to isoflurane and ventilatory response to hypoxia remained in patients anaesthetized with 0.6-1.1 MAC of isoflurane. [4] [5] [6] Animal studies also provide conflicting data as to whether or not HVR is depressed by volatile anaesthetics. 7 8 The site of action of volatile agents on HVR remains unclear. Limited studies in humans suggest that the carotid bodies are the most likely site of action. [9] [10] [11] However, the peripheral chemosensors appear to be active during light halothane anaesthesia. Clergue and co-workers 12 used a method derived from Dejours' test to assess the response to hypoxia from the transient decrease in ventilation after oxygen was substituted for room air, where the time course of response indicates a rapid (peripheral) reflex.
We have assessed if peripheral chemoreceptors are active during isoflurane anaesthesia by observing ventilatory responses to transient hyperoxia during light isoflurane anaesthesia. This test, derived from Dejours' test, is based on the concept that the initial response to hyperoxia (transient ventilatory depression) is mediated by peripheral chemoreceptors which respond more promptly, and that this effect occurs before the onset of secondary responses. The second aim of this study was to see if domperidone, a selective dopamine D 2 receptor antagonist which does not cross the blood-brain barrier, 13 could augment the response to this test in patients anaesthetized with isoflurane. We showed in a previous study 14 that domperidone offset the suppressive effect of isoflurane on HVR, presumably by antagonism of dopamine D 2 receptors in the carotid bodies.
Patients and methods
This double-blind, placebo-controlled study was approved by the local Research Ethics Committee. Written informed consent was obtained from 20 patients who were ASA I, not overweight and aged 18-65 yr. Patients were allocated randomly to receive either domperidone 20 mg or placebo tablets 1 h before arrival in the anaesthetic room.
In the anaesthetic room, an i.v. infusion was commenced and non-invasive monitoring of arterial pressure, ECG and pulse oximetry started. General anaesthesia was induced with etomidate 0.3 mg kg 91 i.v. and anaesthesia was deepened with isoflurane and nitrous oxide in oxygen, with the patient breathing spontaneously. When anaesthesia was judged to be of adequate depth for tracheal intubation, laryngoscopy was performed and the larynx sprayed with a metered dose of a lignocaine preparation (Xylocaine, Astra Pharmaceuticals) using no more than 40 mg. After a short delay, the trachea was intubated and the inspired oxygen concentration was reduced to and maintained at 20% for the duration of the study. At the same time, the inspired isoflurane concentration was adjusted to obtain a stable end-tidal concentration of 0.4%, as measured by a Brüel and Kjaer gas monitor 1304, sampling at 90 ml min
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, with a response time of less than 360 ms. 15 Headphones were placed on the patient's ears and white noise was played to prevent noise affecting breathing, and the arterial pressure cuff was not automatically inflated routinely in case it altered breathing pattern. Measurements of ventilatory variables during anaesthesia were started after a stable end-tidal isoflurane concentration had been present for at least 20 min.
The tracheal tube was connected via a screen pneumotachograph (F100L, Mercury Electronics) to an Ambu Hesse non-rebreathing valve. The pneumotachograph pressure signal was measured with a Furness FC044 differential pressure transducer (Ϯ10 mm H 2 O). The inspiratory side of the valve was connected to a large bore two-way tap which allowed rapid changes between two supply systems. Anaesthetic gases (20% oxygen, isoflurane and nitrous oxide) were provided from a 4-litre reservoir bag fitted with a spill valve to reduce positive pressure in the supply tubing. Oxygen was supplied (flow rate of 6 litre min
) from a T-piece system using a 1-m length of anaesthetic tubing as a reservoir. The deadspace of the breathing system was approximately 80 ml.
Inspired and expired carbon dioxide and oxygen partial pressures and inspired and expired concentrations of isoflurane were measured continuously by the Brüel and Kjaer gas monitor. Gas monitor and flow signals were recorded on a lap-top computer using the commercial respiratory monitoring software Cardas (version 2.07 advanced, Oxcams, Oxford), running in MS-DOS (version 6.2) for later off-line analysis. The flow signal was integrated to obtain values for tidal volume (VT) and instantaneous minute ventilation (VE inst ) calculated from tidal volume and respiratory cycle duration. Before each study, the pneumotachograph was calibrated against a 1-litre calibration syringe and the gas monitor was calibrated using a reference gas.
When clinically stable anaesthesia was achieved, the tap was turned during expiration so that two breaths of 100% oxygen were given. Tests were repeated at 2-min intervals. Five satisfactory two-breath oxygen tests were recorded. At the end of the testing sequence, a venous blood sample was obtained for measurement of plasma concentrations of domperidone and surgery started.
ANALYSIS AND STATISTICS
We measured the 10 breaths before the two hyperoxic breaths as baseline. We ignored the two hyperoxic breaths (test breaths) and the following two breaths, as it required these additional breaths to elapse for exhaled oxygen to return to pre-test values. We then measured the eight subsequent breaths ( fig. 1) . Previous work has shown that maximum change in ventilation occurs after six breaths from the change in inspired oxygen.
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To reduce the influence of normal variation in breathing, the five hyperoxic tests for each patient were averaged on a breath-by-breath basis. We calculated means and 95% confidence limits (CL) for VE inst and mean inspiratory flow rate (VT/TI) for the 10 breaths used as baseline, and inspected the post-test breaths for a reduction to less than 95% CL of baseline. If any post-test breath was reduced below the 95% CL of baseline, this was considered a definite response provided that breaths increased again towards baseline after reaching a minimum value ( fig. 1 ). From the VT/TI results, we recorded the post-test breath number with the smallest VT/TI. This breath was used subsequently for analysis of frequency, and inspiratory and expiratory time changes from baseline. The time from the hyperoxic stimulus to the breath with the smallest VT/TI was also noted.
To assess the reliability and consistency of this method of analysis, a random selection of five sets of 22 breaths was obtained in each patient during baseline breathing and subjected to the same averaging and analysis to assess if similar results could be obtained without the hyperoxic test breaths. Definite responses for both the placebo and domperidone groups were compared for any significant difference using the chi-square test with Yates' correction.
To assess if domperidone augmented the response to the hyperoxic test breaths, the mean maximal reductions in VE inst and VT/TI from baseline was calculated for both the placebo and domperidone groups. These values, and TI and TE changes from baseline, based on the minimum VT/TI post-test breath, were compared between groups using the Mann-Whitney test. Statistical significance was set at the 5% level.
Results
All patients completed the study without complications. The placebo and domperidone groups were comparable in age (mean 33 (range 26-53) and 34 (22-56) yr, respectively), weight (mean 73 (SD 15) and 72 (15) kg, respectively) and sex distribution (5M, 5F and 6M, 4F, respectively). Mean oxygen saturations were 92.7 (SD 2.3) % and 93.3 (1.9) %, respectively, and no patient had an oxygen saturation less than 90% when breathing an inspired oxygen concentration of 20%. Mean baseline end-tidal carbon dioxide partial pressures before the oxygen tests were 5.5 (range 4.5-6.0) kPa for the placebo group and 5. (table  2) . These changes were statistically significantly (P:0.02).
Timing variables (TI and TE) for the minimum post-test VT/TI breath were compared with respective mean baseline values. With the exception of data from two patients in the placebo group, inspiratory times were lengthened after the test in both groups compared with baseline values (table 1). The mean increase in inspiration time for the placebo group was 0.04 s and 0.12 s for the domperidone group (table 2) . There was a significant difference between groups (P:0.02). Expiration times were more variable but the trend was towards increasing expiration time in both groups (table 1). The mean increase for both groups was 0.06 s (table 2) .
Mean plasma concentration of domperidone in the domperidone group was 7.9 (range 2.0-19.3) ng ml
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. There was no correlation between plasma concentrations of domperidone and the size of the transient reductions in VE inst or VT/TI.
Discussion
We have shown that peripheral chemoreceptor activity was present in a majority of patients during isoflurane anaesthesia. Pre-existing stimulus to breathing was shown by transient depression of both VE inst and VT/TI after two breaths of 100% oxygen. With domperidone pretreatment, patients showed greater reductions in both VE inst and VT/TI after two breaths of 100% oxygen.
We reduced the respiratory depresent effects of other anaesthetic agents in this study by using etomidate for induction of anaesthesia, which has a short duration of action, and by avoiding the use of opioids. We averaged the repeated tests in each individual to reduce breath-to-breath variability so that small changes in ventilatory variables (as produced by this transient hyperoxia test) were more likely to be detected. Our method of testing for a definite response to hyperoxia is similar to that used in human studies involving single-breath carbon dioxide tests of peripheral chemosensitivity. 16 Randomly selected breaths subjected to the same analysis did not demonstrate the clear pattern of reduction followed by recovery towards baseline and we believe that this method of analysis reliably detected transient changes in responses. In our analysis, we ignored the two hyperoxic breaths (test breaths) and the following two breaths as there was a delay for the expired oxygen to return to baseline and we did not correct the pneumotachograph for changes in gas composition. As previous work showed that the maximum change occurred six breaths after the change in inspired oxygen, 11 we were unlikely to have missed the maximum change.
We used a variation of Dejours' test to assess the activity of the peripheral chemoreceptors during isoflurane anaesthesia. With this technique in resting awake humans, the magnitude of ventilatory change is approximately 8-10% of pre-stimulus baseline ventilation and occurs approximately 10 s after the stimulus. 17 In our study, during isoflurane anaesthesia, mean ventilatory change was 4.9% in the placebo group and 7.7% in the domperidone group and mean time to minimum VT/TI after stimulus was 13.5 s in the placebo group and 14.9 s in the domperidone group. This is longer than in awake subjects. Washin of oxygen to the alveoli and hence the change in arterial oxygen content may take longer during anaesthesia because ventilation is less in the anaesthetized subject. Alternatively, control of ventilation may be different from the awake state.
There are possible drawbacks of this test to assess chemoreceptor activity during anaesthesia. Hyperoxia can increase blood 2 CO a P via the Haldane effect and thereby cause an increase in ventilation. Furthermore, hyperoxia can reduce cerebral blood flow which would tend to increase brain PCO 2 and thus also ventilation. 18 These effects, which are probably less rapid than effects at the peripheral chemoreceptors, would tend to oppose the decrease in ventilation caused by hyperoxia and therefore underestimate the magnitude of the ventilatory output of the peripheral chemoreceptors.
Duffin, Triscott and Whitwam 11 studied patients after opioid premedication and found that 0.7-0.8% halothane in air substantially decreased the ventilatory response to two breaths of oxygen compared with the response during thiopentone anaesthesia. Others have studied patients anaesthetized with 1.5% halothane, using a method derived from Dejours' test, and found that peripheral chemoreceptor activity was depressed but not abolished. 12 Knill and coworkers 3 found that even at 0.1 MAC of isoflurane, there was a 50% reduction in the ventilatory response to isocapnic hypoxia. This was confirmed recently by van den Elsen and colleagues 10 who extended the concentration of isoflurane to 0.2 MAC and found a 65% reduction in isocapnic HVR. At anaesthetic concentrations of 1.1 MAC, HVR was virtually abolished. 3 This suggested that HVR and therefore the peripheral chemoreflex pathway was highly sensitive to the effects of isoflurane. However, our results and those of Clergue and co-workers 12 suggest that peripheral chemoreceptors are not "silent" at anaesthetic concentrations of isoflurane and halothane, respectively, suggesting that although peripheral chemoreceptor responses are depressed, this is perhaps not to the degree as suggested by previous investigators. 3 Our findings also support recent studies by Lindahl's group [4] [5] [6] who found persistent ventilatory responses to hypoxia under poikilocapnic conditions in patients anaesthetized with 0.6-0.85 MAC of isoflurane and a reduction of 60-70% in HVR under isocapnic conditions with 0.85-1.1 MAC of isoflurane. Therefore, anaesthetic concentrations of isoflurane do not appear to suppress HVR to the same extent as that found by previous investigators. 3 10 Differences in experimental conditions may account for some of these differences. 10 Washin studies of subanaesthetic halothane and isoflurane 9 10 suggest that the most likely site of action of volatile agents is at the peripheral chemoreceptors. Depression of hypoxaemic-driven ventilation by halothane and isoflurane occurred extremely rapidly, within the first minute of inhalation. For isoflurane, it was estimated that after 30 s of isoflurane inhalation, the carotid body isoflurane tension would be approximately 90% of end-tidal, whereas the brain isoflurane tension would be approximately 8% of end-tidal. 10 Therefore, ventilatory depression occurring within 30 s of isoflurane inhalation is best explained by an action of isoflurane at the peripheral chemoreceptors. However, Whitwam and co-workers 19 demonstrated in anaesthetized patients that there was a mean delay of only 10 s in central chemoreceptor ventilatory response to i.v. injection of sodium bicarbonate (causing an increase in 2 CO a P ) when peripheral chemoreceptor activity was depressed by hyperoxia. This suggests that the time lag between the effect of isoflurane at central and peripheral chemoreceptor sites during washin could also be in the region of 10 s. Therefore, a central effect of subanaesthetic isoflurane cannot be excluded in the first 30 s of isoflurane washin and overall suppression of HVR at anaesthetic doses could be caused by a combination of peripheral and central effects.
The second aim of this study was to determine if domperidone, a selective dopamine D 2 receptor antagonist which does not readily cross the blood-brain barrier, 13 could augment the response to transient hyperoxia in patients anaesthetized with isoflurane. Domperidone augments HVR in humans 20 and can offset the suppression caused by isoflurane on the ventilatory response to hypoxia. 14 We found that with domperidone pretreatment, all patients showed positive results to transient hyperoxia suggesting that with increased ventilatory drive, it was easier to demonstrate the transient reductions in both VE inst and VT/TI after two breaths of 100% oxygen.
Analysis using VT/TI instead of breath-by-breath minute ventilation demonstrated a greater difference between placebo and domperidone. VT/TI is a measure of respiratory drive allowing minute ventilation to be separated into drive and timing components: VE inst is the product of VT/TI and TI/TTOT (timing component where TTOT is the sum of TI and TE). 21 When inspiratory and expiratory times were compared between groups, only TI was significantly different, with domperidone causing an increase in inspiration time. These results support the observations of Clergue and co-workers who found a prompt change in TI after oxygen breathing commenced. 12 In summary, our data support the view that peripheral chemoreceptors remain active during isoflurane anaesthesia. Their function may be depressed by isoflurane, but perhaps not as much as suggested previously. Domperidone enhanced peripheral chemosensor activity by increasing respiratory drive during isoflurane anaesthesia.
